The phase 4 ANNEXA-I trial was stopped early after showing superior hemostatic efficacy and the capability to limit potentially life-threatening intracerebral hemorrhage (ICH) compared with usual care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results